PULMATRIX, INC. Restricted Cash and Cash Equivalents
PULMATRIX, INC. (PULM) had Restricted Cash and Cash Equivalents of $153.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCashAndCashEquivalents · last filed 2022-11-10
- 2022-09-30: Restricted Cash and Cash Equivalents $153.00K.
- 2022-06-30: Restricted Cash and Cash Equivalents $153.00K.
- 2022-03-31: Restricted Cash and Cash Equivalents $1.63M.
- 2021-12-31: Restricted Cash and Cash Equivalents $1.63M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2022-09-30 | $153.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $153.00K 10-Q · filed 2022-08-10 |
| 2022-03-31 | $1.63M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.63M 10-K · filed 2022-03-29 |
| 2021-09-30 | $204.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $204.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $204.00K 10-Q · filed 2022-05-12 |
| 2020-12-31 | $204.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $204.00K 10-Q · filed 2021-11-10 |
| 2020-06-30 | $204.00K 10-Q · filed 2021-08-10 |
| 2020-03-31 | $204.00K 10-Q · filed 2021-05-11 |
| 2019-12-31 | $204.00K 10-K · filed 2021-03-23 |
| 2019-09-30 | $204.00K 10-Q · filed 2020-11-12 |
| 2019-06-30 | $204.00K 10-Q · filed 2020-08-07 |
| 2019-03-31 | $204.00K 10-Q · filed 2020-05-14 |
| 2018-12-31 | $204.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | $204.00K 10-Q · filed 2019-11-01 |
| 2018-06-30 | $204.00K 10-Q · filed 2019-08-05 |
| 2018-03-31 | $204.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |